Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Daniel G Welch. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Daniel G Welch har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:RARE / Ultragenyx Pharmaceutical Inc. | Director | 32 690 |
US:NUVB / Nuvation Bio Inc. | Director | 659 947 |
US:SGEN / Seagen Inc | Director | 0 |
US:GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) | Director | 123 508 |
US:ICPT / Intercept Pharmaceuticals Inc | Director | 2 966 |
US:AVXS / AveXis, Inc. | Director | 0 |
US:HPTX / Hyperion Therapeutics Inc | Director | 0 |
US:ITMN / | Chairman, CEO and President, Director | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Daniel G Welch. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock). Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock). Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp NUVB.WS / Panacea Acquisition Corp. - Equity Warrant - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock). Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel NUVB.WS / Panacea Acquisition Corp. - Equity Warrant - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock). Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Daniel G Welch som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-19 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 5 740 | 32 690 | 21,30 | ||||
2024-06-20 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 5 345 | 26 950 | 24,74 | ||||
2024-05-29 |
|
4 | NUVB |
Nuvation Bio Inc.
Class A Common Stock |
M - Exercise | 366 744 | 659 947 | 125,08 | 1,64 | 601 460 | 1 082 313 | |
2024-05-29 |
|
4 | NUVB |
Nuvation Bio Inc.
Class A Common Stock |
M - Exercise | 293 203 | 293 203 | 1,74 | 510 173 | 510 173 | ||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | −10 725 | 0 | −100,00 | 229,00 | −2 456 025 | ||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | −4 750 | 0 | −100,00 | 229,00 | −1 087 750 | ||
2023-08-29 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 610 | 10 725 | −13,05 | 209,08 | −336 619 | 2 242 383 |
2023-08-29 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 812 | 6 794 | −21,06 | 209,01 | −378 726 | 1 420 014 |
2023-08-29 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 503 | 8 606 | −14,87 | 209,16 | −314 367 | 1 800 031 |
2023-08-29 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 812 | 10 109 | 21,84 | 135,63 | 245 762 | 1 371 084 | |
2023-06-09 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 3 860 | 21 605 | 21,75 | ||||
2023-06-02 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 2 044 | 8 297 | 32,69 | ||||
2023-05-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 864 | 6 253 | −22,96 | 200,02 | −372 837 | 1 250 725 |
2023-05-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 864 | 8 117 | 29,81 | 135,63 | 252 814 | 1 100 909 | |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −5 835 | 12 335 | −32,11 | 200,07 | −1 167 408 | 2 467 863 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −351 | 6 253 | −5,31 | 200,07 | −70 225 | 1 251 038 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −3 462 | 6 604 | −34,39 | 200,10 | −692 746 | 1 321 460 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 3 462 | 10 066 | 52,42 | 147,50 | 510 645 | 1 484 735 | |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −3 171 | 6 604 | −32,44 | 200,05 | −634 359 | 1 321 130 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 3 171 | 9 775 | 48,02 | 160,33 | 508 406 | 1 567 226 | |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 888 | 6 604 | −22,23 | 200,05 | −377 694 | 1 321 130 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 888 | 8 492 | 28,59 | 64,38 | 121 549 | 546 715 | |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −4 890 | 18 170 | −21,21 | 200,06 | −978 293 | 3 635 090 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −295 | 6 604 | −4,28 | 200,06 | −59 018 | 1 321 196 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 990 | 6 899 | −22,39 | 200,12 | −398 239 | 1 380 628 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 990 | 8 889 | 28,84 | 56,77 | 112 972 | 504 629 | |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −5 150 | 6 899 | −42,74 | 200,04 | −1 030 206 | 1 380 076 |
2023-05-03 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 5 150 | 12 049 | 74,65 | 64,38 | 331 557 | 775 715 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −4 284 | 12 335 | −25,78 | 202,54 | −867 681 | 2 498 331 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −3 317 | 16 619 | −16,64 | 201,51 | −668 409 | 3 348 895 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −3 124 | 19 936 | −13,55 | 200,45 | −626 206 | 3 996 171 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 082 | 4 149 | −20,68 | 202,54 | −219 148 | 840 338 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −851 | 5 231 | −13,99 | 201,51 | −171 485 | 1 054 099 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −817 | 6 082 | −11,84 | 200,45 | −163 768 | 1 219 137 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −112 | 6 899 | −1,60 | 203,05 | −22 742 | 1 400 842 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 112 | 7 011 | 1,62 | 56,77 | 6 358 | 398 014 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −7 158 | 6 899 | −50,92 | 202,51 | −1 449 567 | 1 397 116 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 7 158 | 14 057 | 103,75 | 56,77 | 406 360 | 798 016 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −5 | 6 899 | −0,07 | 202,49 | −1 012 | 1 396 979 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 5 | 6 904 | 0,07 | 66,60 | 333 | 459 806 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −3 575 | 6 899 | −34,13 | 201,59 | −720 684 | 1 390 769 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 3 575 | 10 474 | 51,82 | 66,60 | 238 095 | 697 568 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −5 680 | 6 899 | −45,15 | 200,71 | −1 140 033 | 1 384 698 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 5 680 | 12 579 | 82,33 | 66,60 | 378 288 | 837 761 | |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −995 | 6 899 | −12,60 | 200,11 | −199 109 | 1 380 559 |
2023-04-05 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 995 | 7 894 | 14,42 | 38,82 | 38 626 | 306 445 | |
2023-03-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 246 | 23 060 | −5,13 | 200,05 | −249 262 | 4 613 153 |
2023-03-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −320 | 6 899 | −4,43 | 200,05 | −64 016 | 1 380 145 |
2023-03-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 037 | 7 219 | −22,01 | 200,05 | −407 502 | 1 444 161 |
2023-03-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 2 037 | 9 256 | 28,22 | 38,82 | 79 076 | 359 318 | |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −288 | 24 306 | −1,17 | 200,00 | −57 600 | 4 861 200 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −470 | 12 977 | −3,50 | 200,00 | −94 000 | 2 595 400 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 470 | 13 447 | 3,62 | 38,82 | 18 245 | 522 013 | |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −74 | 12 977 | −0,57 | 200,00 | −14 800 | 2 595 400 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −173 | 24 594 | −0,70 | 202,36 | −35 008 | 4 976 842 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −808 | 24 767 | −3,16 | 201,53 | −162 836 | 4 991 294 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −8 210 | 25 575 | −24,30 | 200,20 | −1 643 642 | 5 120 115 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −5 758 | 7 219 | −44,37 | 200,06 | −1 151 945 | 1 444 233 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −44 | 13 051 | −0,34 | 202,35 | −8 903 | 2 640 870 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −214 | 13 095 | −1,61 | 201,53 | −43 127 | 2 639 035 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −2 098 | 13 309 | −13,62 | 200,20 | −420 020 | 2 664 462 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −7 629 | 15 407 | −33,12 | 200,30 | −1 528 089 | 3 086 022 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 7 629 | 23 036 | 49,52 | 39,94 | 304 702 | 920 058 | |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −1 348 | 15 407 | −8,05 | 201,53 | −271 662 | 3 104 973 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 1 348 | 16 755 | 8,75 | 39,94 | 53 839 | 669 195 | |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | −283 | 15 407 | −1,80 | 202,36 | −57 268 | 3 117 761 |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 283 | 15 690 | 1,84 | 39,94 | 11 303 | 626 659 | |
2023-03-16 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 5 758 | 15 407 | 59,67 | 38,82 | 223 526 | 598 100 | |
2023-02-09 |
|
4 | GPCR |
Structure Therapeutics Inc.
Ordinary Shares |
C - Conversion | 123 508 | 123 508 | |||||
2022-06-28 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 3 300 | 17 745 | 22,85 | ||||
2022-05-18 |
|
4 | NUVB |
Nuvation Bio Inc.
Stock Option (Right to Buy) |
A - Award | 118 784 | 118 784 | |||||
2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3 676 | 3 676 | |||||
2022-05-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 503 | 9 649 | 18,45 | ||||
2022-02-11 |
|
5 | SGEN |
Seagen Inc.
Common Stock |
G - Gift | 33 785 | 33 785 | |||||
2022-02-11 |
|
5 | SGEN |
Seagen Inc.
Common Stock |
G - Gift | −33 785 | 8 146 | −80,57 | ||||
2021-11-02 |
|
4 | NUVB |
Nuvation Bio Inc.
Stock Option (Right to Buy) |
A - Award | 45 229 | 45 229 | |||||
2021-06-28 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 4 125 | 4 125 | |||||
2021-06-28 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 2 145 | 14 445 | 17,44 | ||||
2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
A - Award | 3 462 | 3 462 | |||||
2021-05-18 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 1 402 | 41 931 | 3,46 | ||||
2021-02-12 | 3 | NUVB |
Nuvation Bio Inc.
No securities owned. |
0 | ||||||||
2021-02-12 |
|
4 | NUVB |
Nuvation Bio Inc.
Stock Option (Right to Buy) |
A - Award | 312 750 | 312 750 | |||||
2021-02-12 |
|
4 | NUVB |
Nuvation Bio Inc.
Stock Option (Right to Buy) |
A - Award | 86 184 | 86 184 | |||||
2021-02-05 |
|
5 | SGEN |
Seagen Inc.
Common Stock |
G - Gift | −6 819 | 40 529 | −14,40 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −8 750 | 0 | −100,00 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −8 750 | 0 | −100,00 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −9 518 | 0 | −100,00 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −7 982 | 9 518 | −45,61 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 500 | 0 | −100,00 | ||||
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −9 250 | 47 348 | −16,34 | 164,61 | −1 522 642 | 7 793 954 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −14 500 | 56 598 | −20,39 | 165,06 | −2 393 370 | 9 342 066 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 14 500 | 71 098 | 25,62 | 19,02 | 275 790 | 1 352 284 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −9 518 | 56 598 | −14,40 | 165,72 | −1 577 323 | 9 379 421 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 9 518 | 66 116 | 16,82 | 20,06 | 190 931 | 1 326 287 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −7 982 | 56 598 | −12,36 | 166,70 | −1 330 599 | 9 434 887 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 7 982 | 64 580 | 14,10 | 20,06 | 160 119 | 1 295 475 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −8 750 | 56 598 | −13,39 | 167,34 | −1 464 225 | 9 471 109 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 8 750 | 65 348 | 15,46 | 36,70 | 321 125 | 2 398 272 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | −8 750 | 56 598 | −13,39 | 168,24 | −1 472 100 | 9 522 048 | |
2020-11-04 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
M - Exercise | 8 750 | 65 348 | 15,46 | 34,25 | 299 688 | 2 238 169 | |
2020-06-30 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 4 250 | 4 250 | |||||
2020-06-30 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 2 550 | 12 300 | 26,15 | ||||
2020-06-01 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
A - Award | 2 966 | 2 966 | |||||
2020-06-01 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 1 595 | 8 060 | 24,67 | ||||
2020-05-19 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 3 171 | 3 171 | |||||
2020-05-19 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 1 335 | 56 598 | 2,42 | ||||
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −205 | 55 263 | −0,37 | 166,77 | −34 188 | 9 216 211 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −2 435 | 55 468 | −4,21 | 166,23 | −404 770 | 9 220 446 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −4 319 | 57 903 | −6,94 | 164,98 | −712 549 | 9 552 837 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −8 041 | 62 222 | −11,44 | 164,21 | −1 320 413 | 10 217 475 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −284 | 70 263 | −0,40 | 167,99 | −47 709 | 11 803 481 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −11 011 | 70 547 | −13,50 | 167,26 | −1 841 700 | 11 799 691 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −5 400 | 81 558 | −6,21 | 166,27 | −897 858 | 13 560 649 | |
2020-05-07 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
S - Sale | −3 305 | 86 958 | −3,66 | 165,62 | −547 374 | 14 401 984 | |
2020-01-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −17 500 | 0 | −100,00 | ||||
2020-01-09 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 17 500 | 90 263 | 24,05 | 12,76 | 223 300 | 1 151 756 | |
2019-06-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
A - Award | 2 174 | 2 174 | |||||
2019-06-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 1 570 | 6 465 | 32,07 | ||||
2019-06-13 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 5 000 | 5 000 | |||||
2019-06-13 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 3 000 | 9 750 | 44,44 | ||||
2019-05-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 7 038 | 7 038 | |||||
2019-05-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 2 963 | 72 763 | 4,24 | ||||
2018-06-22 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Option to Purchase Common Stock |
A - Award | 2 748 | 2 748 | |||||
2018-06-22 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS, INC.
Common Stock |
A - Award | 1 787 | 4 895 | 57,50 | ||||
2018-06-20 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 5 000 | 5 000 | |||||
2018-06-20 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 3 000 | 6 750 | 80,00 | ||||
2018-05-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 9 260 | 9 260 | |||||
2018-05-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 700 | 69 800 | 5,60 | ||||
2018-05-15 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −2 905 | 0 | −100,00 | ||||
2018-05-15 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −2 454 | 0 | −100,00 | ||||
2018-05-15 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −35 552 | 0 | −100,00 | ||||
2018-05-15 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
D - Sale to Issuer | 1 106 | 0 | −100,00 | ||||
2018-03-30 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | 2 905 | 2 905 | |||||
2018-03-30 |
|
4 | AVXS |
AveXis, Inc.
Common Stock |
A - Award | 1 106 | 1 106 | |||||
2018-02-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2018-02-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −6 881 | 0 | −100,00 | ||||
2018-02-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 6 881 | 66 100 | 11,62 | 8,38 | 57 663 | 553 918 | |
2018-02-15 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 10 000 | 59 219 | 20,32 | 10,08 | 100 800 | 596 928 | |
2017-08-02 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −602 | 3 108 | −16,23 | 123,93 | −74 604 | 385 163 |
2017-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −217 | 3 710 | −5,53 | 126,76 | −27 507 | 470 280 |
2017-06-29 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 2 036 | 2 036 | |||||
2017-06-29 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 1 423 | 3 927 | 56,83 | ||||
2017-06-22 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy) |
A - Award | 3 750 | 3 750 | |||||
2017-06-22 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 1 875 | 3 750 | 100,00 | ||||
2017-06-01 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | 2 454 | 2 454 | |||||
2017-05-23 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 9 260 | 9 260 | |||||
2017-05-23 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 700 | 49 219 | 8,13 | ||||
2016-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 1 598 | 1 598 | |||||
2016-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 1 204 | 2 504 | 92,62 | ||||
2016-06-14 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Employee Stock Option (Right to Buy) |
A - Award | 3 750 | 3 750 | |||||
2016-06-14 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Common Stock |
A - Award | 1 875 | 1 875 | |||||
2016-05-24 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 9 260 | 9 260 | |||||
2016-05-24 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 700 | 45 519 | 8,85 | ||||
2016-03-10 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −25 000 | 0 | −100,00 | ||||
2016-03-10 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 25 000 | 41 819 | 148,64 | 9,82 | 245 500 | 410 663 | |
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | 8 385 | 8 385 | |||||
2016-02-12 |
|
4 | AVXS |
AveXis, Inc.
Stock Option (Right to Buy) |
A - Award | 27 167 | 27 167 | |||||
2016-02-10 | 3 | AVXS |
AveXis, Inc.
Common Stock |
0 | ||||||||
2015-11-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 3 500 | 3 500 | |||||
2015-11-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 1 300 | 1 300 | |||||
2015-06-22 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 7 500 | 7 500 | |||||
2015-05-19 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 9 260 | 9 260 | |||||
2015-05-19 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 700 | 16 819 | 28,20 | ||||
2015-05-08 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −4 869 | 0 | −100,00 | 46,00 | −223 974 | ||
2015-05-08 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −9 800 | 0 | −100,00 | 46,00 | −450 800 | ||
2015-05-08 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −20 000 | 0 | −100,00 | 46,00 | −920 000 | ||
2015-05-08 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
D - Sale to Issuer | −2 617 | 0 | −100,00 | 46,00 | −120 382 | ||
2015-04-10 |
|
4 | RARE |
Ultragenyx Pharmaceutical Inc.
Stock Option (Right to Buy) |
A - Award | 17 500 | 17 500 | |||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
D - Sale to Issuer | −80 000 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
D - Sale to Issuer | −80 000 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
D - Sale to Issuer | −165 000 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
D - Sale to Issuer | −128 975 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
D - Sale to Issuer | −25 000 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Restricted stock units |
D - Sale to Issuer | −42 250 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Performance stock units |
D - Sale to Issuer | −24 000 | 0 | −100,00 | ||||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
D - Sale to Issuer | −23 000 | 0 | −100,00 | 74,00 | −1 702 000 | ||
2014-10-01 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
U - Other | −71 202 | 23 000 | −75,58 | 74,00 | −5 268 948 | 1 702 000 | |
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −24 900 | 0 | −100,00 | ||||
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −24 900 | 94 202 | −20,91 | 45,17 | −1 124 813 | 4 255 406 |
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 24 900 | 119 102 | 26,43 | 8,73 | 217 377 | 1 039 760 |
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −21 025 | 128 975 | −14,02 | ||||
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −125 100 | 24 900 | −83,40 | ||||
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −146 125 | 94 202 | −60,80 | 44,95 | −6 568 684 | 4 234 615 |
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 21 025 | 240 327 | 9,59 | 10,10 | 212 352 | 2 427 303 |
2014-08-07 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 125 100 | 219 302 | 132,80 | 8,73 | 1 092 123 | 1 914 506 |
2014-06-18 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −15 000 | 0 | −100,00 | ||||
2014-06-18 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −15 000 | 94 202 | −13,74 | 45,02 | −675 252 | 4 240 673 |
2014-06-18 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 15 000 | 109 202 | 15,92 | 19,01 | 285 150 | 2 075 930 |
2014-06-05 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | −3 914 | 94 202 | −3,99 | 39,19 | −153 401 | 3 692 040 | |
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Restricted stock units |
M - Exercise | −8 750 | 26 250 | −25,00 | ||||
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | −4 565 | 98 116 | −4,45 | 40,06 | −182 894 | 3 930 959 | |
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | 8 750 | 102 681 | 9,32 | ||||
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
A - Award | 80 000 | 80 000 | |||||
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Performance stock units |
A - Award | 24 000 | 24 000 | |||||
2014-06-02 |
|
4 | ITMN |
INTERMUNE INC
Restricted stock units |
A - Award | 16 000 | 16 000 | |||||
2014-05-29 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (right to buy) |
A - Award | 4 869 | 4 869 | |||||
2014-05-29 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Common Stock |
A - Award | 2 617 | 2 617 | |||||
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −6 493 | 0 | −100,00 | ||||
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −456 | 0 | −100,00 | ||||
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −6 949 | 93 931 | −6,89 | 40,15 | −278 970 | 3 770 888 |
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 6 493 | 100 880 | 6,88 | 15,40 | 99 992 | 1 553 552 |
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 456 | 94 387 | 0,49 | 15,34 | 6 995 | 1 447 897 |
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −9 544 | 456 | −95,44 | ||||
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Stock options (right to buy) |
M - Exercise | −25 000 | 149 999 | −14,29 | ||||
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −34 544 | 93 931 | −26,89 | 40,01 | −1 381 974 | 3 757 822 |
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 9 544 | 128 475 | 8,02 | 15,34 | 146 405 | 1 970 806 |
2014-05-28 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 25 000 | 118 931 | 26,62 | 8,73 | 218 250 | 1 038 268 |
2014-05-21 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | 7 388 | 170 145 | 4,54 | 15,34 | 113 332 | 2 610 024 | |
2014-05-21 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | 4 219 | 162 757 | 2,66 | 15,34 | 64 719 | 2 496 692 | |
2014-05-21 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | X | −11 607 | 93 931 | −11,00 | 38,00 | −441 066 | 3 569 378 |
2014-05-21 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
M - Exercise | X | 11 607 | 105 538 | 12,36 | 15,34 | 178 051 | 1 618 953 |
2014-05-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 8 750 | 8 750 | 34,25 | 299 688 | 299 688 | ||
2014-05-20 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 500 | 13 119 | 36,39 | ||||
2014-05-14 |
|
4 | ITMN |
INTERMUNE INC
Common stock |
S - Sale | −4 175 | 93 931 | −4,26 | 36,14 | −150 873 | 3 394 403 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | 6 518 | 158 538 | 4,29 | 15,34 | 99 986 | 2 431 973 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | 1 | 152 020 | 0,00 | 15,34 | 15 | 2 331 987 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | 25 000 | 152 019 | 19,68 | 8,73 | 218 250 | 1 327 126 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −31 519 | 98 106 | −24,32 | 36,01 | −1 135 012 | 3 532 836 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 6 518 | 129 625 | 5,29 | 15,34 | 99 986 | 1 988 448 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 1 | 123 107 | 0,00 | 15,34 | 15 | 1 888 461 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 25 000 | 123 106 | 25,48 | 8,73 | 218 250 | 1 074 715 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | 3 913 | 127 019 | 3,18 | 25,55 | 99 977 | 3 245 335 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | 25 000 | 123 106 | 25,48 | 8,73 | 218 250 | 1 074 715 | |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −28 913 | 98 106 | −22,76 | 33,39 | −965 370 | 3 275 642 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 3 913 | 127 019 | 3,18 | 25,55 | 99 977 | 3 245 335 |
2014-05-07 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 25 000 | 123 106 | 25,48 | 8,73 | 218 250 | 1 074 715 |
2014-04-03 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −3 673 | 98 106 | −3,61 | 33,57 | −123 287 | 3 293 006 |
2014-03-05 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | −15 655 | 121 779 | −11,39 | 31,52 | −493 483 | 3 838 766 | |
2014-02-27 |
|
4 | ITMN |
INTERMUNE INC
Common Stock (Right to Buy) |
M - Exercise | −41 087 | 0 | −100,00 | ||||
2014-02-27 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −41 087 | 137 434 | −23,02 | 32,63 | −1 340 767 | 4 484 801 |
2014-02-27 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 41 087 | 178 521 | 29,90 | 25,55 | 1 049 773 | 4 561 212 |
2014-02-05 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −20 000 | 117 434 | −14,55 | 13,08 | −261 600 | 1 536 037 |
2014-01-21 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −50 000 | 37 434 | −57,19 | 18,02 | −901 085 | 674 624 |
2014-01-14 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −50 000 | 87 434 | −36,38 | 17,00 | −850 040 | 1 486 448 |
2013-12-04 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −20 000 | 137 434 | −12,70 | 13,99 | −279 800 | 1 922 702 |
2013-10-03 |
|
4 | ITMN |
INTERMUNE INC
Stock Option (Right to Buy) |
M - Exercise | X | −50 000 | 324 999 | −13,33 | |||
2013-10-03 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
S - Sale | X | −70 000 | 157 434 | −30,78 | 15,43 | −1 080 016 | 2 429 018 |
2013-10-03 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
M - Exercise | X | 50 000 | 227 434 | 28,18 | 8,73 | 436 500 | 1 985 499 |
2013-06-05 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
F - Taxes | −2 819 | 177 434 | −1,56 | 9,89 | −27 889 | 1 755 426 | |
2013-06-03 |
|
4 | ITMN |
INTERMUNE INC
Stock Option (Right to Buy) |
A - Award | 165 000 | 165 000 | |||||
2013-06-03 |
|
4 | ITMN |
INTERMUNE INC
Restricted Stock Units |
A - Award | 35 000 | 35 000 | |||||
2013-05-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 8 750 | 8 750 | 36,70 | 321 125 | 321 125 | ||
2013-05-21 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
A - Award | 3 500 | 9 619 | 57,20 | ||||
2013-05-13 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
F - Taxes | −3 007 | 180 253 | −1,64 | 9,27 | −27 863 | 1 670 242 | |
2013-05-01 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (right to buy) |
A - Award | 9 800 | 9 800 | |||||
2012-12-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 119 | 6 881 | −31,19 | ||||
2012-12-04 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 3 119 | 6 119 | 103,97 | 8,38 | 26 137 | 51 277 | |
2012-09-05 |
|
4 | HPTX |
HYPERION THERAPEUTICS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2012-07-31 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
M - Exercise | −3 000 | 14 500 | −17,14 | ||||
2012-07-31 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Common Stock |
M - Exercise | 3 000 | 3 000 | 19,02 | 57 060 | 57 060 | ||
2012-06-11 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
F - Taxes | −23 341 | 183 260 | −11,30 | 10,02 | −233 877 | 1 836 265 | |
2012-06-06 |
|
4 | ITMN |
INTERMUNE INC
Stock Option (Right to Buy) |
A - Award | 150 000 | 150 000 | |||||
2012-06-06 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
A - Award | 30 000 | 206 601 | 16,99 | 10,10 | 303 000 | 2 086 670 | |
2012-06-06 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
A - Award | 30 000 | 206 601 | 16,99 | 10,10 | 303 000 | 2 086 670 | |
2012-05-22 |
|
4 | SGEN |
SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy) |
A - Award | 17 500 | 17 500 | 20,06 | 351 050 | 351 050 | ||
2012-05-14 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
F - Taxes | −2 064 | 212 601 | −0,96 | 11,75 | −24 248 | 2 497 637 | |
2012-05-14 |
|
4 | ITMN |
INTERMUNE INC
Common Stock |
F - Taxes | −2 935 | 214 665 | −1,35 | 11,54 | −33 862 | 2 476 676 |